SCHEMBL2170684

SCHEMBL2170684

O=C(O)CON=Cc1cc(Cl)c(Oc2ccc(O)c(Cc3ccccc3)c2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 17/20 0.47
THRA P10827 16/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170680 1.00 THRB (0.47) THRBTHRA
SCHEMBL2170106 0.88 THRB (0.54) THRBTHRA
SCHEMBL2170109 0.88 THRB (0.54) THRBTHRA
SCHEMBL2182816 0.84 THRB (0.66) THRBTHRA
SCHEMBL2169449 0.84 THRB (0.66) THRBTHRA
SCHEMBL2170897 0.80 THRA (0.66) THRBTHRA
SCHEMBL2170800 0.79 LMNA (0.43) THRB
SCHEMBL2170803 0.79 LMNA (0.43) THRB
SCHEMBL2169747 0.78 THRA (0.55) THRBTHRA
SCHEMBL2169743 0.78 THRA (0.55) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA THRB 2/4885THRA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.